The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Wenjuan Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma, Blood-Brain Barrier, Brain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Brain Tumor Society.
Abstract (Originalsprache)
Background
Most oncology therapeutics have limited distribution into the brain, and developing strategies to overcome this limitation would be clinically impactful. While therapeutic radiation is often cited as a strategy to accomplish this, there are no published studies demonstrating the effect of radiation on drug distribution into the brain or brain tumors.
Methods
Mice were treated with brain radiation (6 Gy × 5, 4 Gy × 10; 40 Gy × 1) and dosed with drugs (levetiracetam, cefazolin, nedisertib, brigimadlin, apitolisib, or GNE-317) at times ranging from just prior to months after radiation. Plasma and tissue drug concentrations were measured by LC-MS/MS.
Results
Radiation did not significantly enhance drug delivery into brain tissue for levetiracetam, cefazolin, GNE-317, apitolisib, or nedisertib at any time post-radiation. Even a single, supra-therapeutic dose of radiation (40 Gy) did not significantly affect brain distribution of GNE-317 or apitolisib (P ≥ .07) from 16 to 160 hours post-radiation. For brigimadlin, radiation (6 Gy × 5) was associated with a modest but significant increase in drug accumulation only at 72 hours post-radiation (brain-to-plasma ratio 0.014 ± 0.006 vs. 0.025 ± 0.010, respectively; P = .04), but not at any other timepoint (24 hours, 15, 28, 94, 133, 183 days; P > .05). Similarly, radiation (6 Gy × 5) of orthotopic tumors did not increase levels of brigimadlin in GBM10 or GBM108 or nedisertib in GBM108 (P > .05).
Conclusions
Radiation had no meaningful impact on drug delivery into brain or brain tumors for the drugs tested.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Paul A Decker, Jann N Sarkaria
Förderung
- NCI NIH HHS
- NIH HHS
- National Brain Tumor Society
- National Institutes of Health
Zitieren
APA
Zhang, W., Grams, M. P., Oberoi, R. K., Oh, J. H., Decker, P. A., Sio, T. T., Talele, S., Wilson, Z. C., Connors, M. A., Bakken, K. K., Carlson, B. L., Ott, L. L., Burgenske, D. M., Tryggestad, E. J., Eckel Passow, J. E., Elmquist, W. F., & Sarkaria, J. N. (2025). The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf093
Vancouver
Zhang W, Grams MP, Oberoi RK, Oh JH, Decker PA, Sio TT, et al. The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf093
BibTeX
@article{Zhang2025,
author = {Zhang, Wenjuan and Grams, Michael P and Oberoi, Rajneet K and Oh, Ju-Hee and Decker, Paul A and Sio, Terence T and Talele, Surabhi and Wilson, Zachary C and Connors, Margaret A and Bakken, Katrina K and Carlson, Brett L and Ott, Lauren L and Burgenske, Danielle M and Tryggestad, Erik J and Eckel Passow, Jeanette E and Elmquist, William F and Sarkaria, Jann N},
title = {The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf093}
}
EUVIMED